MTOR and acute myeloid leukemia: We examined for the first time the in vitro activity of FD268 on a panel of human AML cell lines including HL-60, MOLM-16, Mv-4-11 and KG-1, which are characterized by different PI3K/Akt/mTOR pathway activation patterns.